Evidence map›Paper›PMID 38360682›Full record

ArticleMolecular cancer2024

A novel peptide PDHK1-241aa encoded by circPDHK1 promotes ccRCC progression via interacting with PPP1CA to inhibit AKT dephosphorylation and activate the AKT-mTOR signaling pathway.

Bo Huang, Junwu Ren, Qiang Ma, Feifei Yang, Xiaojuan Pan, Yuying Zhang, Yuying Liu, Cong Wang, Dawei Zhang, Ling Wei and 11 more

Open access · goldAbstract read
In one paragraph

Article in Molecular cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
9.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 39 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Observational
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 3 institutions in 1 country.

Bo Huang *College of Pharmacy, Chongqing Medical University, Chongqing, 400016, P.R. China.
Junwu Ren *College of Pharmacy, Chongqing Medical University, Chongqing, 400016, P.R. China.
Qiang MaCollege of Pharmacy, Chongqing Medical University, Chongqing, 400016, P.R. China.
Feifei YangCollege of Pharmacy, Chongqing Medical University, Chongqing, 400016, P.R. China.
Xiaojuan PanCollege of Pharmacy, Chongqing Medical University, Chongqing, 400016, P.R. China.
Yuying ZhangCollege of Pharmacy, Chongqing Medical University, Chongqing, 400016, P.R. China.
Yuying LiuCollege of Pharmacy, Chongqing Medical University, Chongqing, 400016, P.R. China.
Cong WangDepartment of Urology, Southwest Hospital, Army Medical University, Chongqing, 400038, P.R. China.
Dawei ZhangDepartment of Urology, Southwest Hospital, Army Medical University, Chongqing, 400038, P.R. China.
Ling WeiDepartment of Urology, Southwest Hospital, Army Medical University, Chongqing, 400038, P.R. China.
Lingyu RanDepartment of Kidney, Southwest Hospital, Army Medical University, Chongqing, 400038, P.R. China.
Hongwen ZhaoDepartment of Kidney, Southwest Hospital, Army Medical University, Chongqing, 400038, P.R. China.
Ce LiangCollege of Pharmacy, Chongqing Medical University, Chongqing, 400016, P.R. China.
Xiaolin WangCollege of Pharmacy, Chongqing Medical University, Chongqing, 400016, P.R. China.
Shiming WangCollege of Pharmacy, Chongqing Medical University, Chongqing, 400016, P.R. China.
Haiping LiCollege of Pharmacy, Chongqing Medical University, Chongqing, 400016, P.R. China.
Hao NingCollege of Pharmacy, Chongqing Medical University, Chongqing, 400016, P.R. China.
Ai RanCollege of Pharmacy, Chongqing Medical University, Chongqing, 400016, P.R. China.
Wei LiDepartment of Pharmacy, Chongqing University Cancer Hospital, Chongqing, 400030, P.R. China. liwei.tmmu@163.com.
Yongquan WangDepartment of Urology, Southwest Hospital, Army Medical University, Chongqing, 400038, P.R. China. wangyongquan@aliyun.com.
Bin XiaoCollege of Pharmacy, Chongqing Medical University, Chongqing, 400016, P.R. China. binxiaocqmu@cqmu.edu.cn.
Chongqing Medical University · CNArmy Medical University · CNSouthwest Hospital · CN

Funding

Chongqing Natural Science Foundation Innovation and Development Joint Fund CSTB2022NSCQ-LZX0043Chongqing Talents-Exceptional Young Talents Project CQYC202005044Future Medical Youth Innovation Team Project of Chongqing Medical University W0042Graduate Tutor Team Construction Project of Chongqing CQMUDSTD202210National Natural Science Foundation of China 82373001Natural Science Foundation of Chongqing CSTC2020JCYJ-MSXMX0022Natural Science Foundation of Chongqing CSTC2020JCYJ-MSXMX0337Postdoctoral Science Foundation of Chongqing CSTB2022NSCQ-BHX0707Science and Technology Research Project of Chongqing Municipal Education Commission KJZD-K202100405Top Graduate Talent Cultivation Program of Chongqing Medical University BJRC202105
6 · The paper itself

Abstract

backgroundClear cell renal cell carcinoma (ccRCC) is the most prevalent kidney cancer with high aggressive phenotype and poor prognosis. Accumulating evidence suggests that circRNAs have been identified as pivotal mediators in cancers. However, the role of circRNAs in ccRCC progression remains elusive.

methodsThe differentially expressed circRNAs in 4 paired human ccRCC and adjacent noncancerous tissues ccRCC were screened using circRNA microarrays and the candidate target was selected based on circRNA expression level using weighted gene correlation network analysis (WGCNA) and the gene expression omnibus (GEO) database. CircPDHK1 expression in ccRCC and adjacent noncancerous tissues (n = 148) were evaluated along with clinically relevant information. RT-qPCR, RNase R digestion, and actinomycin D (ActD) stability test were conducted to identify the characteristics of circPDHK1. The subcellular distribution of circPDHK1 was analyzed by subcellular fractionation assay and fluorescence in situ hybridization (FISH). Immunoprecipitation-mass spectrometry (IP-MS) and immunofluorescence (IF) were employed to evaluate the protein-coding ability of circPDHK1. ccRCC cells were transfected with siRNAs, plasmids or lentivirus approach, and cell proliferation, migration and invasion, as well as tumorigenesis and metastasis in nude mice were assessed to clarify the functional roles of circPDHK1 and its encoded peptide PDHK1-241aa. RNA-sequencing, western blot analysis, immunoprecipitation (IP) and chromatin immunoprecipitation (ChIP) assays were further employed to identify the underlying mechanisms regulated by PDHK1-241aa.

resultsCircPDHK1 was upregulated in ccRCC tissues and closely related to WHO/ISUP stage, T stage, distant metastasis, VHL mutation and Ki-67 levels. CircPDHK1 had a functional internal ribosome entry site (IRES) and encoded a novel peptide PDHK1-241aa. Functionally, we confirmed that PDHK1-241aa and not the circPDHK1 promoted the proliferation, migration and invasion of ccRCC. Mechanistically, circPDHK1 was activated by HIF-2A at the transcriptional level. PDHK1-241aa was upregulated and interacted with PPP1CA, causing the relocation of PPP1CA to the nucleus. This thereby inhibited AKT dephosphorylation and activated the AKT-mTOR signaling pathway.

conclusionsOur data indicated that circPDHK1-encoded PDHK1-241aa promotes ccRCC progression by interacting with PPP1CA to inhibit AKT dephosphorylation. This study provides novel insights into the multiplicity of circRNAs and highlights the potential use of circPDHK1 or PDHK1-241aa as a therapeutic target for ccRCC.

Indexed as

Carcinoma, Renal CellKidney NeoplasmsAnimalsCell Line, TumorCell ProliferationGene Expression Regulation, NeoplasticHumansIn Situ Hybridization, FluorescenceMiceMice, NudePeptidesProtein Phosphatase 1Proto-Oncogene Proteins c-aktRNA, CircularSignal TransductionTOR Serine-Threonine KinasesPeptidesPPP1CA protein, humanProtein Phosphatase 1Proto-Oncogene Proteins c-aktRNA, CircularTOR Serine-Threonine KinasesCircPDHK1Clear cell renal cell carcinomaDephosphorylationNovel peptidePPP1CA

Identifiers

PMID38360682
PMCPMC10870583
OpenAlexW4391840182

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.